Clinical Trial Research to Discovery With Actian Vectorwise

Big Data Analytics Reduced from Days to Minutes to Help Prevent Future Death and Disability from Many Conditions

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Actian Corporation (formerly Ingres Corp) today announced that CTSU (the MRC/Cancer Research UK/BHF Clinical Trial Service Unit & Epidemiological Studies Unit of Oxford University) has selected Vectorwise to extract and analyze data pertaining to the causes, prevention and treatment of premature death and disability worldwide. Research data extraction and processing that once took days now takes minutes, thanks to Actian’s record-breaking Vectorwise technology.

The CTSU primarily studies the causes and treatment of chronic diseases such as cancer, heart attack or stroke (which, collectively, account for most adult deaths worldwide). Through its involvement with the UK Biobank project, the unit is collecting many thousands of pieces of information from each of more than half a million volunteers and will make this data available anonymously to the worldwide scientific community.

As UK Biobank involves following thousands of people over many decades, the project aims to show more reliably than ever before why some people develop disease and others do not. This should help to find new ways to prevent death and disability from many different conditions.

Complex data manipulation and examination is at the center of the research. Accuracy is paramount. The worldwide reputation of the CTSU rests upon the precision of its output and the efficiency with which it obtains it. The team at CTSU had previously been frustrated with the speed of data extraction as even modest queries were often taking days to process. Vectorwise slashed this to minutes. The new analytic speed will unlock the potential of future research by allowing investigations without prohibitive delays. Read Full Article